Molecular Partners is advancing a growing pipeline of DARPin therapies for the treatment of severe or life-threatening diseases, with an initial focus on oncology and ophthalmology. Its most advanced oncology candidate, MP0250, is for the treatment of solid tumors and hematological malignancies. In ophthalmology, the most advanced candidate is abicipar in wet age-related macular degeneration (wet AMD). It has been licensed to Allergan and is being tested in two phase III trials.
We collaborate with leading pharmaceutical companies, including Allergan and Janssen, to discover and develop DARPin therapies.
Working together, we aim to speed the delivery of breakthrough therapies for serious diseases while creating value for both sides of the partnership.